News

The results of the phase IIa trial found that EP-2104R was able to detect blood clots not previously seen on magnetic resonance imaging (MRI). Blood clots are a

This notification follows Progen's end-of-phase II meeting with the FDA. According to Progen, manufacturing the first step of PI-88 in-house saves Progen approximately AUD$7.8 million in outsourcing fees

The FDA and Avax have agreed on the trial design and endpoints under a special protocol assessment which will also expedite review of the product. “Our initial phase

This clinical trial was designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a single dose of PTI-202 in healthy volunteers. Pain Therapeutics believes the results

Vioxx is from a class of drugs called Cox-2 inhibitors which block Cox-2 enzymes that are expressed in areas of inflammation, therefore targeting the site of pain. Vioxx

Under the amended agreement, Cobra will complete only one biologics license application batch of the active ingredient for AA4500, the company's injectable enzyme for the treatment of Dupuytren's

This trial is the first follow-on study to Genta's phase III trial of Genasense plus dacarbazine that showed benefit across multiple clinical endpoints in patients with advanced melanoma

The company plans to initiate its phase III program before year-end with the luteinizing hormone-releasing hormone antagonist compound, cetrorelix. The first study of this phase III program will

MLN3897 is one of several small molecules included in the company's small molecule inflammation collaboration with sanofi-aventis. MLN3897 is a small molecule antagonist of CCR1, a chemokine receptor